Serum KL-6 in adult patients with polymyositis and dermatomyositis

Rheumatology

Volumn 39, Issue 6, 2000, Pages 632-636

  Kubo, M ^a   Ihn, H ^a   Yamane, K ^a   Kikuchi, K ^a   Yazawa, N ^a   Soma, Y ^a   Tamaki, K ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

ELISA; Internal malignancy; Interstitial lung disease

Indexed keywords

CARBON MONOXIDE; GLYCOPROTEIN; KL 6; MUCIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; MALE; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR WEIGHT; POLYMYOSITIS; PRIORITY JOURNAL; VITAL CAPACITY;

EID: 0033930910     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/39.6.632     Document Type: Article

References (19)

1. Kohno N, Akiyama M, Kyoizumi S, Tanabe M, Oyama T, Yamakido M. A novel method for screening monoclonal antibodies reacting with antigenic determinants on soluble antigens: a reversed indirect enzyme-linked immunosorbent assay (RI-ELISA). Hiroshima J Med Sci 1987;36:319-23.
2. Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K, Yamakido M. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 1985;18:203-6.
3. Kohno N, Inoue Y, Hamada H et al. Difference in serodiagnostic values among KL-6-associated mucin classified as cluster 9. Int J Cancer 1994;suppl. 8:81-3.
4. Kohno N, Awaya Y, Oyama T et al. KL-6, a mucin-like glycoprotein in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis 1993;148:637-42.
5. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonia activity. Sialylated carbohydrate antigen KL-6. Chest 1989;96:68-73.
6. Inoue Y, Barker E, Daniloff E, Kohno N, Hiwada K, Newman LS. Pulmonary epithelial cell injury and alveolar capillary permeability in Berylliosis. Am J Respir Crit Care Med 1997;156:109-15.
7. Kohno N, Hamada H, Fujioka S, Hiwada K, Yamakido M, Akiyama M. Circulating antigen KL-6 and lactate dehydrogenase for monitoring irradiated patients with lung cancer. Chest 1992;102:117-22.
8. Hamada H, Kohno N, Akiyama M, Hiwada K. Monitoring of serum KL-1 antigen in a patient with radiation pneumonia. Chest 1992;101:858-60.
9. Inoue Y, Nishimura M, Shiode H et al. Evaluation of serum KL-6 levels in patients with pulmonary tuberculosis. Tuber Lung Dis 1995;76:230-3.
10. Kobayashi J, Kitamura S. Serum KL-6 for the evaluation of active pneumonia in pulmonary sarcoidosis. Chest 1996;109:1276-82.
11. Arsura EL, Greenberg AS. Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis. Semin Arthritis Rheum 1988;18:29-37.
12. Hidano A, Torikai S, Uemura T, Shimizu S. Malignancy and interstitial pneumonitis as fatal complication in dermatomyositis. J Dermatol 1992;19:153-60.
13. Airio A, Pukkala E, Isomaki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 1995;22:1300-3.
14. Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977;56:255-86.
15. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975;292:344-7.
16. Takehara K, Moroi Y, Nakabayashi Y, Ishibashi Y. Antinuclear antibodies in localized scleroderma. Arthritis Rheum 1983;26:612-6.
17. Kubo M, Ihn H, Yazawa N, Sato S, Kikuchi K, Tamaki K. Prevalence and antigen specificity of anti-histone antibodies in patients with polymyositis/dermatomyositis. J Invest Dermatol 1999;112:711-5.
18. Targoff IN. Humoral immunity in polymyositis/dermatomyositis. J Invest Dermatol 1993;100:116s-23s.
19. Kobayashi J, Kitamura S. KL-6: Serum marker for interstitial pneumonia. Chest 1995;108:311-5.